Anti-PD-1 antibodies
The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
1. An isolated anti-programmed cell death 1 (PD-1) antibody comprising a heavy chain variable region comprising SEQ ID NO: 53; and a light chain variable region comprising SEQ ID NO: 67.
2. A pharmaceutical composition comprising an isolated anti-PD-1 antibody comprising a heavy chain variable region comprising SEQ ID NO: 53; and a light chain variable region comprising SEQ ID NO: 67.